China Cancer Antibodies Market Trends Clinical Trials Analysis Report 2023 30 Cancer Antibodies Commercially Approved and More than 800 in Clinical Trials - Yahoo Finance
| 688166 Stock | 30.92 1.21 4.07% |
About 55% of BrightGene Bio's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding BrightGene Bio Medical suggests that some traders are interested. The current market sentiment, together with BrightGene Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use BrightGene Bio Medical stock news signals to limit their universe of possible portfolio assets.
BrightGene |
China Cancer Antibodies Market Trends Clinical Trials Analysis Report 2023 30 Cancer Antibodies Commercially Approved and More than 800 in Clinical Trials Yahoo Finance
Read at news.google.com
 |
BrightGene Bio Fundamental Analysis
We analyze BrightGene Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BrightGene Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BrightGene Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
BrightGene Bio is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
BrightGene Bio Medical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BrightGene Bio stock to make a market-neutral strategy. Peer analysis of BrightGene Bio could also be used in its relative valuation, which is a method of valuing BrightGene Bio by comparing valuation metrics with similar companies.
Peers
BrightGene Bio Related Equities
| 601665 | Qilu Bank | 4.90 | ||||
| 601319 | Peoples Insurance | 1.27 | ||||
| 600901 | Jiangsu Financial | 0.19 | ||||
| 301190 | Jiujiang Shanshui | 0.32 | ||||
| 000524 | Guangzhou Dongfang | 0.42 | ||||
| 002152 | GRG Banking | 1.94 | ||||
| 002124 | Ningbo Tech | 1.97 | ||||
| 002185 | Tianshui Huatian | 2.76 |
Complementary Tools for BrightGene Stock analysis
When running BrightGene Bio's price analysis, check to measure BrightGene Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BrightGene Bio is operating at the current time. Most of BrightGene Bio's value examination focuses on studying past and present price action to predict the probability of BrightGene Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BrightGene Bio's price. Additionally, you may evaluate how the addition of BrightGene Bio to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |